B. Riley Securities Reiterates Buy on Climb Bio, Raises Price Target to $30
B. Riley Securities analyst Mayank Mamtani reiterates Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $26 to $30.
Stocks · News reference
Climb Bio Says Single 320 mg CLYM116 Dose Suppressed APRIL Over 90%, IgA 60-75% Through 12 Weeks In Phase 1 Healthy Volunteers; Sees Phase 2 IgA Nephropathy Data H1 2027
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BTIG Maintains Buy on Climb Bio, Raises Price Target to $32
BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $20 to $32.
Baird Maintains Outperform on Climb Bio, Raises Price Target to $25
Baird analyst Colleen Kusy maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $21 to $25.
Climb Bio’s Kidney Disease Therapy Gets Support for Extended Dosing Schedule
Climb Bio announced positive Phase 1 data for CLYM116 and outlined its strategy to advance the IgA nephropathy candidate into Phase 3.